Neuropsychiatric adverse effects of mefloquine - What do we know and what should we do?
Malaria is still one of the most important tropical diseases, killing millions every year. The number of effective drugs is limited, because of the ability of the causative parasite Plasmodium falciparum to develop drug resistance. Mefloquine, if possible in combination with an artemisinin derivativ...
Main Authors: | Nosten, F, van Vugt, M |
---|---|
Format: | Journal article |
Language: | English |
Published: |
1999
|
Similar Items
-
Multimorbidity: What Do We Know? What Should We Do?
by: Rokas Navickas, et al.
Published: (2016-01-01) -
Neuropathic pain; what we know and what we should do about it
by: Peter A. Smith
Published: (2023-09-01) -
Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?
by: Rosa Cortese, et al.
Published: (2022-12-01) -
Cultured meat production: what we know, what we don’t know and what we should know
by: Maria Olenic, et al.
Published: (2023-12-01) -
Interpersonal violence against athletes <subtitle>What we know, what we need to know, and what we should do</subtitle>
by: Ralph E. Schmidt, et al.
Published: (2022-05-01)